Cetera Investment Advisers boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 73.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 21,126 shares of the medical research company’s stock after buying an additional 8,937 shares during the quarter. Cetera Investment Advisers’ holdings in Thermo Fisher Scientific were worth $11,634,000 at the end of the most recent quarter.
Several other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Thermo Fisher Scientific by 1.3% during the third quarter. Vanguard Group Inc. now owns 32,166,910 shares of the medical research company’s stock worth $16,314,735,000 after acquiring an additional 406,844 shares during the period. BlackRock Inc. raised its stake in Thermo Fisher Scientific by 0.8% during the 3rd quarter. BlackRock Inc. now owns 30,689,762 shares of the medical research company’s stock valued at $15,565,540,000 after acquiring an additional 256,512 shares in the last quarter. State Street Corp boosted its position in Thermo Fisher Scientific by 0.8% during the 3rd quarter. State Street Corp now owns 16,158,876 shares of the medical research company’s stock worth $8,200,398,000 after acquiring an additional 135,437 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.8% in the fourth quarter. Geode Capital Management LLC now owns 6,879,351 shares of the medical research company’s stock valued at $3,780,655,000 after acquiring an additional 123,256 shares in the last quarter. Finally, Amundi lifted its holdings in shares of Thermo Fisher Scientific by 5.3% in the fourth quarter. Amundi now owns 3,130,286 shares of the medical research company’s stock valued at $1,820,245,000 after buying an additional 157,303 shares during the period. Institutional investors and hedge funds own 85.92% of the company’s stock.
Thermo Fisher Scientific Stock Performance
Shares of TMO stock opened at $523.69 on Tuesday. Thermo Fisher Scientific Inc. has a 12 month low of $475.77 and a 12 month high of $611.06. The firm has a market capitalization of $202.00 billion, a PE ratio of 34.14, a price-to-earnings-growth ratio of 2.57 and a beta of 0.79. The firm has a fifty day simple moving average of $543.64 and a two-hundred day simple moving average of $554.34. The company has a current ratio of 1.27, a quick ratio of 0.92 and a debt-to-equity ratio of 0.69.
Thermo Fisher Scientific Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 14th. Shareholders of record on Thursday, June 15th will be issued a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a yield of 0.27%. The ex-dividend date is Wednesday, June 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.13%.
Insider Transactions at Thermo Fisher Scientific
In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, May 5th. The shares were sold at an average price of $545.22, for a total value of $5,452,200.00. Following the completion of the transaction, the chief executive officer now directly owns 141,330 shares of the company’s stock, valued at approximately $77,055,942.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, CEO Marc N. Casper sold 1,600 shares of the company’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $534.82, for a total transaction of $855,712.00. Following the sale, the chief executive officer now directly owns 141,330 shares in the company, valued at $75,586,110.60. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $545.22, for a total transaction of $5,452,200.00. Following the sale, the chief executive officer now directly owns 141,330 shares in the company, valued at approximately $77,055,942.60. The disclosure for this sale can be found here. Corporate insiders own 0.32% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have commented on TMO shares. Barclays decreased their target price on shares of Thermo Fisher Scientific from $625.00 to $610.00 in a report on Thursday, April 27th. Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $693.00 to $670.00 in a research note on Thursday, April 27th. Citigroup decreased their price objective on shares of Thermo Fisher Scientific from $700.00 to $650.00 in a report on Thursday, April 27th. Evercore ISI cut their price target on Thermo Fisher Scientific from $615.00 to $610.00 and set an “outperform” rating for the company in a report on Tuesday, April 4th. Finally, Morgan Stanley lowered their target price on shares of Thermo Fisher Scientific from $670.00 to $620.00 in a research note on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $631.31.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
- Get a free copy of the StockNews.com research report on Thermo Fisher Scientific (TMO)
- Can Cardinal Health Fly Higher In 2023?
- DraftKings Stock, Is There Royally Good Upside Ahead?
- Disney Stock Could Double: Return To Historical Performance
- For AI Exposure, Try Global Artificial Intelligence ETF
- 3 Penny Stocks The Insiders Are BuyingÂ
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
